Catfish Blues
Player Valuation: £15m
Coronavirus: Protein treatment trial 'a breakthrough'
Synairgen says preliminary results suggest its nebuliser treatment can lower the risk of disease.
It hasn't been peer reviewed yet, and it would likely be a few months before it could be approved for general use, but it sounds very hopeful in that it looks like it could be used to treat the majority of hospitalised cases, meaning they wouldn't need intensive care.
It doesn't mention it in the article, but the more treatments there are also potentially helps vaccine development. If there are successul treatments, it reduces the risks associated with challenge vaccine trials ( were volunteers are purposefully exposed to the virus after being vaccinated ).